Circulating histones as clinical biomarkers in critically ill conditions

Jose Luis García‐Giménez(Universitat de València), Juan Carlos Ruiz‐Rodríguez(Universitat Autònoma de Barcelona), Ricard Ferrer(Universitat Autònoma de Barcelona), Raquel Durá(Hospital General Universitario De Valencia), Antonio Artigas(Centre for Biomedical Network Research on Rare Diseases), Iván Bajaña(Universitat Autònoma de Barcelona), David Bolado López de Andujar(Hospital Clínico Universitario de Valencia), Irene Cánovas‐Cervera(Universitat de València), Adrián Ceccato(Centre for Biomedical Network Research on Rare Diseases), Luis Chiscano‐Camón(Universitat Autònoma de Barcelona), Elena Climent‐Martinez(Hospital Clínico Universitario de Valencia), Georgia García Fernández(Hospital Clínico Universitario de Valencia), Gemma Gomà(Hospital General Universitario De Valencia), Verónica Monforte(Hospital General Universitario De Valencia), Beatriz Quevedo‐Sánchez(Hospital Clínico Universitario de Valencia), Adolf Ruiz‐Sanmartín(Universitat Autònoma de Barcelona), Antonio Sierra‐Rivera(Hospital General Universitario De Valencia), Nieves Carbonell Monleón(Hospital Clínico Universitario de Valencia)
FEBS Letters
June 17, 2025
Cited by 4Open Access
Full Text

Abstract

Extracellular histones, primarily nuclear proteins involved in chromatin organization, have emerged as key mediators in pathological processes in critically ill patients. When released into circulation due to cell death mechanisms such as NETosis, histones act as damage-associated molecular patterns (DAMPs), contributing to excessive inflammation, endothelial dysfunction, immune response dysregulation, coagulation activation, cell death, and multi-organ damage. Increasing evidence supports their role in the pathophysiology of sepsis, acute lung injury, cardiac injury, pancreatitis, and other life-threatening conditions. Given their strong association with disease severity and prognosis, circulating histones have gained attention as potential clinical biomarkers for early diagnosis, prognosis, and therapeutic monitoring in critically ill patients. This review discusses the biological roles of extracellular histones, their potential as biomarkers, different approaches to measure them, and emerging therapeutic strategies aimed at neutralizing or removing circulating histones to improve patient outcomes in severe medical conditions. Impact statement This review highlights extracellular histones as key mediators and biomarkers in sepsis, proposing their use in diagnosis, prognosis, and treatment monitoring. Integrating quantitative proteomics for the detection of circulating histones may enhance patient stratification and guide therapeutic strategies, advancing personalized medicine in critical care.


Related Papers

No related papers found

Powered by citation graph analysis